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Acute kidney injury (AKI) remains to be an independent risk factor for mortality and morbidity. Inﬂammation is now believed to
play a major role in the pathopathophysiology of AKI. It is hypothesized that in ischemia, sepsis and nephrotoxic models that the
initial insult results in morphological and/or functional changes in vascular endothelial cells and/or in tubular epithelium. Then,
leukocytes including neutrophils, macrophages, natural killer cells, and lymphocytes inﬁltrate into the injured kidneys. The injury
inducesthegenerationofinﬂammatorymediatorslikecytokinesandchemokinesbytubularandendothelialcellswhichcontribute
to the recruiting of leukocytes into the kidneys. Thus, inﬂammation has an important role in the initiation and extension phases
of AKI. This review will focus on the mediators of inﬂammation contributing to the pathogenesis of AKI.
Copyright © 2009 Ali Akcay et al. This is an open access article distributed under the Creative Commons Attribution License,
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1.Introduction
Acute kidney injury (AKI) occurs in 1% of hospital admis-
sions [1] and up to 7% of hospitalized patients develop AKI
[1]. Twenty ﬁve percent of patients in the intensive care
unit (ICU) develop AKI and 5% of patients in the ICU
will need renal replacement therapy [1, 2]. AKI is usually
diagnosed by increases in serum creatinine or blood urea
nitrogen. Recently urinary biomarkers like interleukin-18
(IL-18), kidney injury molecule-1 (KIM-1), and neutrophil
gelatinase-associated lipocalin (NGAL) have been used for
the early diagnosis of AKI [3]. Dialysis is the only Federal
Drug Administration- (FDA-) approved treatment for AKI
[4]. Even though both intermittent hemodialysis (IHD) and
continuous renal replacement therapy (CRRT) are widely
used, the mortality of AKI is as high as 80% in ICU patients
[5, 6]. A better understanding of the inﬂammatory response
in AKI is needed to allow interventions which would prevent
the need for hemodialysis, shorten the course of AKI, reduce
distant organ injury in AKI, and improve survival.
AKI remains to be an independent risk factor for mortal-
ity and morbidity. AKI increases the risk of death in patients
after thoracoabdominal aortic surgery [7], after bone mar-
row transplantation [8], after amphotericin B therapy [9],
following cardiac surgery [10], and in patients with liver
cirrhosis [11]. An increase in serum creatinine is a risk factor
for mortality in hospitalized [12] and ICU patients [13]. An
increase in plasma proinﬂammatory cytokine levels predicts
mortality in patients with AKI [14]. Potential tubular and
vascular factors, as well as inﬂammatory processes, are
involved in the pathogenesis of AKI [15]. Inﬂammation is
now believed to play a major role in the pathophysiology of
AKI[16,17].Thevascularendotheliumplaysacentralrolein
the recruitment and migration of circulating inﬂammatory
cells into sites of inﬂammation [18]. In addition, several
authors have demonstrated the renoprotective eﬀects of
various anti-inﬂammatory therapies, for example, mycophe-
nolate, alpha-melanocyte stimulating hormone (α-MSH)
targeting the proinﬂammatory pathways that participate in
the pathogenesis of AKI [19]. The present review focuses
on inﬂammatory mediators like cytokines, chemokines,
neutrophils, lymphocytes, natural killer (NK) cells, and
macrophages in AKI (Figure 1).
Experimental studies in AKI have utilized ischemia-
reperfusion, sepsis-endotoxemia, and nephrotoxic models
[20]. These models of AKI are associated with a strong
inﬂammatory reaction. It is hypothesized that in ischemia,
sepsis, and nephrotoxic models that the initial insult results
in morphological and/or functional changes in vascular
endothelial cells and/or in tubular epithelium [15, 21].
Then, leukocytes including neutrophils, macrophages, nat-
ural killer cells, and lymphocytes inﬁltrate into the injured2 Mediators of Inﬂammation
kidneys. The injury induces the generation of inﬂammatory
mediators like cytokines and chemokines by tubular and
endothelial cells which contribute to the recruiting of
leukocytes into the kidneys (Table 1). Thus, inﬂammation
plays an important role in the initiation and extension
phases of AKI. This review will focus on the mediators of
inﬂammation contributing to the pathogenesis of AKI.
2.RenalEndothelialCells
Renal vascular endothelial cells initiate early inﬂammatory
responses in the injured kidney because of direct contact
with injurious agents [22]. Using intravital two-photon
microscopy and the FVB-TIE2/GFP mouse [23], in which
theendotheliumisﬂuorescent,ithasbeendemonstratedthat
ischemicinjurydamagesthebarrierfunctionofendothelium
resultingindisorganizationofendothelialintegrityincluding
the partial disappearance of cell-cell borders and interrup-
tion of cell-cell contacts. Thus, endothelial disintegration
increases vascular permeability and facilitates leukocyte
inﬁltration into the renal parenchyma. Recent studies have
investigated the leukocyte-endothelium interactions. Netrin-
1 is an anti-inﬂammatory molecule ﬁrst discovered in the
brain. Netrin-1 plays an important role in the control of
neuronal navigation during development of the nervous sys-
tem and has also been shown to contribute to the patterning
of developing epithelial tissues [24]. It has been determined
that downregulation of netrin-1 in renal vascular endothelial
cells in peritubular capillaries may promote endothelial cell
activation resulting in inﬁltration of leukocytes into the
kidney and tubular injury [25]. Sphingosine 1-phospate
maintains endothelial cell integrity and inhibits lymphocyte
extravasations via the sphingosine 1-phospate receptor.
A recent study showed that a sphingosine 1-phospate-
selectiveagonistamelioratesischemicacuterenalfailure[26].
Additionally, renal endothelial prostacyclin synthesis may
contribute to renal protection against endotoxemia-related
AKI by maintaining the systemic and renal hemodynamic
parameters [27]. Also, endothelial cells have a major role in
the accumulation of leukocytes by expressing the adhesion
molecules and chemokines (discussed in later sections).
3. Renal TubularEpithelium
Renal tubular epithelium is a major site of cell injury and
death during AKI. Several studies have suggested that renal
tubular epithelial cells play a proinﬂammatory role in AKI.
Interferon regulatory factor-1 (IRF-1) is a transcription
factor known to activate proinﬂammatory genes, including
interferons and chemokines. A recent study has demon-
strated that IRF-1 is an early critical proinﬂammatory signal
stimulated by reactive oxygen species during ischemic injury
in vitro and in vivo and is produced within S3 proximal
tubule cells. Transgenic knockout of IRF-1 ameliorated the
impairment of renal function, morphologic injury, and
inﬂammation after acute ischemia [28]. The Rho kinase
pathway plays an important role in dediﬀerentiation of
epithelial cells and inﬁltration of inﬂammatory cells. A study
has investigated the blockade of the Rho kinase cascade
within renal tubular cells and the interstitium. Inhibition
of Rho kinase with the renally targeted Y27632-lysozyme
conjugate strongly inhibits tubular damage, inﬂammation,
and ﬁbrogenesis induced by ischemia/reperfusion injury
indicated by reduced staining of the dediﬀerentiation marker
kidney injury marker-1 (KIM-1) and increased E-cadherin
relative to controls [29] .K I M - 1i sa ni m m u n o g l o b u l i n
superfamily cell surface molecule expressed on epithelial
cells after injury. Increased expression of KIM-1 on injured
epithelial cells transforms the epithelial cells into phagocytes
that can clear apoptotic and necrotic cells [30]. Phagocytosis
of dead cells mediated by KIM-1 upregulation may inﬂuence
the inﬂammatory response in AKI [30]. We will now
review the roles of other mediators of inﬂammation such as
complement, chemokines, cytokines, and toll-like receptors
(TLRs) that regulate or are released by the renal tubular
epithelial cells, renal endothelial cells, and inﬂammatory
cells.
4. Cytokines
Many cytokines are released by leukocytes and renal tubular
cells into the injured kidney and are important components
of both the initiation and extension of inﬂammation in AKI.
The proinﬂammatory cytokines/chemokines IFNγ,I L - 2 ,I L -
10, GM-CSF, TGF-β, CXCL1, IL-6, MIP-2, and MCP-1 are
increased in the kidney in ischemic AKI [31–35].
Caspase-1 is a proinﬂammatory caspase via its activation
of the cytokines IL-1β and IL-18. Administration of IL-
1 receptor antagonist to mice is not protective against
ischemic AKI [36]. IL-1β deﬁcient mice are not protected
against ischemic AKI [36]. Thus IL-18 was investigated as
a potential mediator of the protection against ischemic AKI
in caspase-1 deﬁcient mice. IL-18 is a proinﬂammatory
cytokine produced by proximal tubules [37], lymphocytes
[38], neutrophils [39], and macrophages [40] in ischemic
AKI. Activation of IL-18 by caspase-1 results in produc-
tion of several cytokines and chemokines, activation of
T helper cells, and proliferation of lymphocytes. It was
demonstrated that caspase-1 deﬁcient mice are functionally
and histologically protected against ischemic AKI and that
this protection is associated with decreased conversion of IL-
18 precursor to the mature form in the kidney [41]. In this
study, the administration of IL-18-neutralizing antiserum
also protected against ischemic acute renal failure [41]. In
subsequent studies, it was determined that IL-18 binding
protein (a natural inhibitor of IL-18) overproducing trans-
genic mice are protected against ischemic AKI [42]. A recent
study conﬁrmed the pathogenic role of IL-18 in ischemic
AKI in mice: pretreatment of wild-type mice with IL-18-
binding protein is renoprotective and IL-18 deﬁcient mice
are protected against ischemic AKI [43]. IL-18-mediated
ischemic AKI has neutrophil- and macrophage-independent
mechanisms [39, 40].
Cisplatin-induced AKI is associated with increases in
the cytokines IL-1β,I L - 1 α, IL-6, and IL-18 and neutrophil
inﬁltration in the kidney [44]. However, inhibition ofMediators of Inﬂammation 3
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Figure 1: Inﬂammatory pathogenesis of AKI. AKI results in the upregulation of chemokines like fractalkine and CXCL1 and adhesion
molecules like P-selectin in the endothelium of blood vessels in the kidney. Upregulation of chemokines and adhesion molecules in
the endothelium results in the inﬁltration of inﬂammatory cells like neutrophils (N), lymphocytes (L), and macrophages (M) from the
blood vessels into the interstitium of the kidney. Proximal tubular epithelial cells produce cytokines like IL-18 and IL-6. IL-18 and IL-
6 produced by the proximal tubule enter the interstitium and result in activation and/or proliferation of neutrophils (N), lymphocytes
(L), and macrophages (M). IL-18 and IL-6 are also released from the proximal tubular cells into the tubular lumen where they serve as
early urinary diagnostic biomarkers of AKI. Inﬂammatory cells produce vasoconstrictors (prostaglandins, leukotrienes, and thromboxanes)
that may aﬀect vascular injury and oxygen radicals that may worsen tubular and vascular injury. Resident dendritic cells (DCs) form a
contiguous network throughout the entire kidney. The role of DCs in AKI is not well understood. Following kidney ischemia-perfusion,
resident dentritic cells release cytokines like TNF and IL-6 and chemokines like MCP-1.
IL-1β, IL-6, and IL-18 and neutrophils by IL-1 receptor
antagonist, IL-6 (−/−) mice, IL-18 antiserum, IL-18 binding
protein transgenic mice, or neutrophil-depleting antibody
respectively was not suﬃcient to prevent cisplatin-induced
AKI [44].
Caspase-1 deﬁcient mice are protected against cisplatin-
induced AKI [45] and endotoxemia-induced AKI [46].
The mechanism of protection against cisplatin-induced AKI
and endotoxemia-induced AKI in caspase-1 deﬁcient mice
remains to be determined. TNF-alpha is a potent proinﬂam-
matory cytokine and important mediator of inﬂammatory
tissue damage. Cisplatin-induced AKI causes TNF-alpha
synthesis.Cisplatin[47,48]andendotoxin-induced[49]AKI
is mediated in-part by TNF-alpha and the inhibition of the
release or action of TNF-alpha protects the kidney from
nephrotoxicity.
Alpha-MSHisanimportantanti-inﬂammatorymolecule
that inhibits IL-8 and intracellular adhesion molecule-
1 (ICAM-1) and signiﬁcantly reduces renal injury after
ischemia reperfusion in both wild-type and neutrophil
depleted models [50, 51]. Recently, the administration
of AP214 (an analogue of alpha-MSH) was reported to
ameliorate sepsis-induced AKI and mortality in mice [52].
Interleukin-10 (IL-10) is a potent anti-inﬂammatory
cytokine that inhibits inﬂammatory and cytotoxic path-
ways implicated in acute renal injury. IL-10 protects
against ischemic AKI and cisplatin-induced AKI. IL-10
may act, in part, by inhibiting the maladaptive activation
of genes that cause leukocyte activation and adhesion
[53].
IL-6 is a proinﬂammatory cytokine that has been shown
to mediate ischemic AKI [32, 54] and lung injury in mice
with AKI [55]. IL-6 can stimulate target cells via a soluble
form of the IL-6 Receptor in a process called trans-signaling
[54]. The mechanism of the eﬀect of IL-6 in ischemic AKI
may be related to trans-signaling and STAT3 activation in
renal tubular cells.
5. Chemokines
Chemokines are a large subgroup of cytokine-like molecules
that play a major role in the recruitment of leukocytes
in inﬂammation and in the regulation of T helper-
1/T helper-2 immune responses. Chemokines have been
divided into four subfamilies-CXC, CC, C, and CX3C-
according to the number and spacing of conserved cys-
teine residues in their sequences [56]. Chemokines are
induced by cytokines (TNF-α and IL-1β), complement
activation, reactive oxygen species, NF-KB system, and TLR-
related pathways [56]. It has been reported that various
chemokines and chemokine receptors contribute to tissue
injury in animal models of inﬂammatory kidney disease
[56].4 Mediators of Inﬂammation
The chemokine receptor CCR1 regulates traﬃcking of
macrophages and neutrophils to the kidney in a mouse
model of renal ischemia-reperfusion injury [57]. Wild-
type mice pretreated with the speciﬁc CCR1 antagonist
BX471 and CCR1 deﬁcient mice had fewer neutrophils and
macrophages than control mice. Also, CCR1 deﬁcient mice
had reduced content of the CCR1 ligands CCL3 (MIP-
1alpha) and CCL5 (RANTES).
Proinﬂammatory cytokines increase expression of the
CX3C chemokine, fractalkine, on injured endothelial cells.
The fractalkine receptor (CX3CR1) is expressed on natural
killer (NK) cells, monocytes, and some CD8+ T cells
[18]. Fractalkine has a mucin-like stalk that extends the
chemokine domain away from the endothelial cell surface
enabling presentation of the CX3C-chemokine domain to
leukocytes. Expression of fractalkine enables bypassing of
the ﬁrst 2 steps of the adhesion cascade (i.e., rolling and
triggering) and mediates cell adhesion between circulating
leukocytes and endothelial cells as well as extravasation of
these cells. Thus, fractalkine serves the dual function of an
adhesion molecule and a chemoattractant [18]. Fractalkine
is a major chemoattractant for NK cells and monocytes
but not neutrophils [58]. Fractalkine expression is increased
in patients with renal tubulointerstitial inﬂammation with
the strongest expression localized to vascular sites near
to macrophage inﬂammation [59]. Fractalkine is a strong
candidatefordirectingmononuclearcellinﬁltrationinduced
by vascular injury [59]. Fractalkine expression is increased
in the endothelium of large blood vessels, capillaries, and
glomeruli in ischemic AKI and fractalkine receptor inhi-
bition is protective against ischemic AKI [60]. Fractalkine
expression is also increased in the blood vessels in mouse
kidneys exposed to cisplatin [61]. However fractalkine
inhibition did not protect against the functional and his-
tological abnormalities in cisplatin-induced AKI in mice
[61]
CXCL1 (also known as KC or IL-8), a prototypic CXC
chemokine, is a neutrophil chemoattractant and attracts
both neutrophils and T lymphocytes to the site of inﬂamma-
tion [62]. It has been previously demonstrated that CXCL1
is increased in the kidney in ischemic AKI [33, 34, 63].
Studies suggest that CXCL1 is a mediator of ischemic AKI.
Injection of a neutralizing antibody to CXCL1 in mice
results in decreased neutrophil inﬁltration in the kidney and
protection against ischemic AKI [64]. CXCL1 binds to the
chemokine receptors CXCR1 and CXCR2. In a rat model
of renal transplantation, repertaxin, a CXCR2 inhibitor,
prevents granulocyte inﬁltration in the kidney and prevents
deterioration of kidney function [65]. CXCL1 is made
by monocytes/macrophages, ﬁbroblasts, keratinocytes, and
endothelial cells [62, 66]. In ischemic AKI, CXCL1 staining
was detected in macrophages and tubular epithelial cells.
Macrophage depletion is known to be protective against
ischemic AKI in mice [67, 68]. A key question is the
mechanism of this protective eﬀect. A possible mechanism
of this protective eﬀect is inhibition of production of CXCL1
by macrophages in ischemic AKI. Thus, it was determined
whether macrophages are the source of CXCL1 in the kidney
in ischemic AKI [42]. Inhibition of macrophage inﬁltration
Table 1: Inﬂammatory mediators of AKI.
Caspases
Caspase-1
Alpha-MSH
Cytokines
(IFN-γ)
(TGF-β)
(TNF-α)
(IL-6)
(IL-10)
(IL-18)
Chemokines
( C X C L 1( a l s ok n o w na sK Co rI L - 8i nm i c e ) )
(CX3CL1 (also known as fractalkine))
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TLR-2
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TLR-9
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CD4
CD8
Bc e l l s
Tregs
NK cells
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Dendritic cells
in the kidney using liposomal encapsulated clodronate pre-
vented the increase in CXCL1 in the kidney suggesting that
macrophagesarethemainsourceofCXCL1inischemic AKI.
In view of the inhibition of CXCL1 production in the kidney
by macrophage depletion and the documented protective
eﬀect of CXCL1 inhibition in ischemic AKI [64, 65], it is
possible that part of the protective eﬀect of macrophage
depletion in ischemic AKI is mediated by inhibition of
CXCL1.
6. Adhesion Molecules
Adhesion molecules are required for leukocyte adhesion
during inﬂammation. Leukocyte adhesion to endothelial
cells leads to inﬂammation and extension of cellular injuryMediators of Inﬂammation 5
[69].ICAM-1playsanimportantroleinthepathophysiology
of AKI [70, 71]. The administration of a monoclonal
ICAM-1 antibody and ICAM-1 deﬁcient mice is protected
against renal ischemia [72, 73]. Pretreatment with topical
polyethylene glycol hydrogel delivery of ICAM-1 antisense
oligonucleotides demonstrated decreased ICAM-1 mRNA
expression, reduced ICAM-1 protein staining, and decreased
cellular damage in a murine partial nephrectomy/ischemia
model [74].
The selectins and their ligands are other important
adhesion molecules that participate in the inﬂammatory
response. P-selectin is expressed as part of the inﬂammatory
stimulus in platelets and endothelial cells, L-selectin is
expressed in leukocytes and lymphocytes, and E-selectin is
expressed in endothelium. Renal ischemia has been shown
to be associated with upregulation of endothelial P-selectin
but not L-selectin, with enhanced adhesion of neutrophils
[75]. Studies have demonstrated that inhibition of P-selectin
ameliorates the inﬂammatory response and ischemic AKI
in rats and mice [76–78] and endotoxemia-induced AKI
in rabbits [79]. A selectin ligand inhibitor, TBC-1269, was
reported to provide protection against both short- and
long-term eﬀects of AKI in a pig model [78, 80]. E-
selectin and its ligands are essential for extravasation of
leukocytes in inﬂammation. CD147 (also known as Basigin
or Bsg) is a membrane glycoprotein that belongs to the
immunoglobulin superfamily and is a ligand for E-selectin.
A recent study has indicated that CD147 is responsible
for neutrophil recruitment in renal ischemia/reperfusion
[81]. Compared with wild-type mice, CD147-deﬁcient
mice demonstrated signiﬁcant suppression of neutrophil
inﬁltration in the kidney after renal ischemia/reperfusion
[81].
7. Complement System andToll-Like Receptors
The complement system eﬀectively identiﬁes and clears
hazardous agents as well as injured host cells. Uncontrolled
complement activation can also contribute to tissue injury,
however, and inhibition of this system may ameliorate many
types of inﬂammatory injury. Complement activation in the
kidney after ischemia-reperfusion was reported to occur pri-
marily via the alternative pathway [82]. Selective inhibition
ofthealternativepathwayprovidedprotectionfromischemic
kidneyinjury[83].Treatmentwithaninhibitorymonoclonal
antibody to mouse factor B, a necessary component of the
alternative pathway, prevented activation of complement
in the kidney after ischemia-reperfusion and protected the
mice from necrotic and apoptotic tubular injury [84].
The complement inhibitor, complement receptor 1-related
protein y (Crry), is expressed by proximal renal tubules
on the basolateral membrane. Loss of polarity of Crry in
the tubular epithelium preceded the activation of alternative
pathway along the basolateral aspect of the tubular cells.
After ischemia/reperfusion, altered renal tubular expression
ofCrrywasreportedtopermitcomplementactivation.Crry-
deﬁcient mice are more susceptible to ischemia, conﬁrming
the protective role of Crry expression [85]. A recent study
showedthatC3a(theﬁrstcomponentofthealternativepath-
way) is required for the production of macrophage inﬂam-
matory factor (MIP-2/CXCL2) and keratinocyte-derived
chemokine (KC/CXCL1/IL-8) by proximal tubular epithelial
cells after renal ischemia/reperfusion. Selective antagonism
of the C3a receptor signiﬁcantly attenuated production
of MIP-2 and KC, whereas C5a receptor antagonism and
prevention of membrane attack complex (MAC) formation
didnothaveasigniﬁcanteﬀectonMIP-2andKCproduction
[34].
TLRs are a family of transmembrane receptors that are
widely expressed on leukocytes and kidney epithelial cells
and regulate innate and adaptive immune responses. Renal
tubular epithelial cells are known to express TLR-2 and 4,
and expression of TLR-2 and TLR-4 was reported to increase
during endotoxemic, ischemic, and nephrotoxic AKI [86].
TLR-2 deﬁcient mice and mice treated with TLR-2 antisense
oligonucleotides are protected from ischemic renal injury
[87]. It has been demonstrated that systemic endotoxin has
direct access to renal sites where TLR-4 is expressed [88]. A
signiﬁcant increase in TLR-4 expression by tubular epithelial
cells and inﬁltrating leukocytes was demonstrated in the kid-
neyfollowingischemia[88,89].TLR-4(−/−)miceengrafted
with wild-type hematopoietic cells had signiﬁcantly lower
serum creatinine and less tubular damage than wild-type
mice reconstituted with TLR-4 (−/−)b o n em a r r o w[ 88].
Tamm-Horsfall protein (THP) is a glycoprotein with unclear
functions expressed in thick ascending limbs of the kidney.
Using THP knockout mice, the roles of THP and TLR-
4 were investigated in renal ischemia-reperfusion injury.
It was demonstrated that THP protects the kidney from
ischemic injury by decreasing inﬂammation and altering
TLR-4 expression during renal ischemia [90]. A recent study
has investigated the eﬀect of chloroquine, an inhibitor of
TLR-3, 7, 8, and 9, in a polymicrobial sepsis mouse model
[91]. Chloroquine administration attenuated the decline
in renal function and serum pro- and anti-inﬂammatory
cytokines like TNF-alpha and IL-10. Administration of an
oligodeoxynucleotide inhibitor (H154) of TLR9 and TLR9-
deﬁcient mice demonstrated attenuation of AKI and a
decrease in serum pro- and anti-inﬂammatory cytokines.
Thus chloroquine and inhibition of TRP-9 protect from
sepsis-induced AKI [91]. Another recent study demon-
strated that TLR-4 signaling mediates inﬂammation and
tissue injury in cisplatin-induced AKI [92]. Cisplatin-treated
wild-type mice had signiﬁcantly more renal dysfunction,
histological damage, leukocyte inﬁltration in the kidney,
and higher levels of cytokines in serum, kidney, and urine
than cisplatin- treated mice with a targeted deletion of
TLR-4.
8. Inﬂammatory Cells
8.1. Neutrophils. The adherence of neutrophils to the vascu-
lar endothelium is the ﬁrst step in the extravasation of these
cells into injured tissue. After adherence and chemotaxis,
inﬁltrating neutrophils can release reactive oxygen species
that damage the tubular cells [93].6 Mediators of Inﬂammation
ThepreciseroleofneutrophilsinAKIhasbeenaddressed
inmanystudiesandremainscontroversial[94,95].Ischemic,
nephrotoxic, and endotoxemia-induced AKI are associated
with an increase in inﬁltrating neutrophils in the kidney [39,
41, 44, 89, 96]. There is evidence that neutrophils mediate
tubular injury in AKI and play a key role in the development
ofacuterenalfailure[94].Thisevidenceisderivedfromstud-
iesthatshowanaccumulationofneutrophilsinischemicAKI
and studies demonstrating a beneﬁcial role of anti-ICAM-1
therapy in AKI [73]. In addition, mice depleted of peripheral
neutrophils by antineutrophil serum were protected against
ischemic AKI [73]. Also, a recent study demonstrated that
rapid CD44 upregulation on renal capillary endothelial cells
mediates neutrophil recruitment to the postischemic tissue
inarenalischemia-perfusionmousemodel.CD44deﬁciency
or administration of anti-CD44 to mice reduced the inﬂux
of neutrophils into the postischemic tissue, associated with
renal function preservation [97].
However, in another study, rats depleted of peripheral
neutrophils by antineutrophil serum were not protected
against ischemic AKI [98]. Also, mice injected with the
rat IgG2b monoclonal antibody RB6-8C5 that results in
peripheral blood neutrophil depletion had a small (18%)
reduction in serum creatinine during ischemic AKI but no
reduction in the ATN score despite a lack of neutrophil
inﬁltration in the kidney [39, 99]. In addition caspase-1
activity and IL-18 were still signiﬁcantly increased in the
kidney in neutrophil-depleted mice with AKI [39].
A recent study investigated the role of cathepsin G release
by the activated neutrophils in renal ischemia-perfusion
injury, using cathepsin G knockout mice. The study demon-
strated that cathepsin G is required for sustained neutrophil-
mediated inﬂammation and tissue injury after reperfusion of
ischemic kidneys [100].
In summary, there are studies demonstrating both an
injurious and noninjurious role of neutrophils in AKI. Inter-
estingly, AKI is still seen in neutropenic patients suggesting
that neutrophil depletion alone is not suﬃcient to protect
against AKI.
8.2. Lymphocytes. T h er o l eo fl y m p h o c y t e si nA K Ii sa n
ongoing area of study. Lymphocytes have been shown to be
important modulators of innate and adaptive inﬂammatory
responses in AKI models [101] .I no n es t u d y ,m i c ew i t ha
combined deﬁciency of both CD4 and CD8 T cells were
protected against ischemic AKI [102]. In a follow-up report
by the same investigators, nu/nu mice deﬁcient in both
CD4 and CD8 T cells were also protected from AKI and
adoptivetransferofTcellsintothesemicereconstitutedrenal
injury [103]. CD4 knockout mice, but not CD8 knockout
mice, were markedly protected against ischemic AKI and
adoptivetransferofCD4Tcellsintothesemicerestoredrenal
injury [103, 104]. CD4 T cells can functionally diﬀerentiate
into either a T helper 1 (IFN-gamma producing) or the
counterbalancing T helper 2 (IL-4 producing) phenotype.
A study of CD4 T cell subsets in ischemia reperfusion
induced-AKI demonstrated that the T helper 1 phenotype is
pathogenic and the T helper 2 phenotype can be protective
[105]. Mice deﬁcient in B lymphocytes alone are also
protected against ischemic AKI [106]. The eﬀect of T cells
on vascular permeability in ischemic AKI in CD3, CD4, and
CD8 T cell deﬁcient mice was investigated and demonstrated
that T cells directly contribute to the increased renal vascular
permeability after ischemia-reperfusion, likely via T cell
cytokine production (TNF-alpha and INF-gamma) [107]. In
contrast, in another study, depletion of CD4 cells using the
GK 1.5 antibody was not suﬃcient to prevent ischemic AKI
in mice [38].
The role for T lymphocytes in cisplatin-induced AKI
was examined with T cell deﬁcient (nu/nu) mice and CD4-
and CD8-deﬁcient mice and their wild-type littermates. T
cell-deﬁcient and CD4-deﬁcient mice were protected from
cisplatin-induced AKI and adoptive transfer of T cells into
nu/nu mice enhanced renal dysfunction and tubular injury
[108].
Recent studies have focused on the role of regulatory
T cells (Tregs) in ischemic AKI. Tregs are a subtype
of lymphocytes that have strong immunosuppressive and
anti-inﬂammatory properties. Tregs are identiﬁed by their
expression of CD4 and CD25 on the cell surface and
upregulationoftheFoxP3,auniquemarkerforTregcellsthat
is essential for their development and function [109]. Tregs
have been reported to mediate ischemic AKI through IL-10
mediated suppression of the innate immune system [110].
Partial depletion of Tregs with an anti-CD25 monoclonal
antibody worsened ischemic kidney damage and resulted in
more neutrophil and macrophage inﬁltration in the kidney
and increased innate cytokine transcription in the kidney.
FoxP3+ Treg-deﬁcient mice accumulated a greater number
of leukocytes while Treg repletion signiﬁcantly attenuated
renal injury and leukocyte accumulation. Adoptive transfer
of wild-type Tregs into RAG-1 knockout mice was suﬃcient
to prevent kidney injury. However, transfer of IL-10 deﬁcient
Tregsdidnotpreventischemicinjury[110].Pharmacological
recruitment of Tregs is a potential future therapy for AKI.
8.3. Natural Killer Cells. NK cells are a type of lympho-
cyte that mediates innate immunity against pathogens and
tumors via their ability to secrete cytokines [111]. NK cells
are unique in their constitutive expression of receptors for
cytokines and chemokines. NK cells in mice express mostly
the same receptors as humans including NK 1.1. A model of
NKcellactivationininjuredtissueshasbeenproposed[112].
Inthis model, it is hypothesized thatNK cellsare recruitedto
sites of injury from the bloodstream. Once in the tissue, NK
cells become activated and release cytokines like IL-18 [112].
In support of this hypothesis, it is known that NK cells play a
role in numerous disease processes [113].
NK cells are increased in the kidney in adriamycin
nephropathy but depletion of NK cells using antiasialo GM-
1 antibody is not protective against adriamycin nephropathy
[114]. A recent study investigated the role of NK cells in
renaltubularepithelialcellsincultureandinmice.Thestudy
demonstrated for the ﬁrst time that NK cells can directly kill
epithelial cells and that NK cells induce apoptosis in tubular
epithelial cells and contribute to renal ischemia-reperfusionMediators of Inﬂammation 7
injury. NK cell depletion in wild-type mice was protective
against AKI, while adoptive transfer of NK cells worsened
AKIinNKcell,Tcell,andBcell-nullRag-2(−/−)gamma(c)
(−/−) mice with AKI [115].
Natural killer T cells (NKT cells) are another interesting
s u b t y p eo fl y m p h o c y t e sa n dh a v es o m eo ft h ec h a r a c t e r i s t i c s
of T and NK cells. NKT cells have regulatory functions by
releasingcytokinesandIFN-gamma.NKTcellactivationwas
reported to mediate neutrophil and IFN-gamma production
in ischemic AKI in mice [116]. It has been demonstrated
that isoﬂurane anesthesia protected against ischemic AKI
by reducing inﬂammation and modulating renal neutrophil,
macrophage, and NKT cell inﬂux in mice [117]
8.4. Macrophages. Macrophages are well-known sources of
proinﬂammatory caspases and cytokines like IL-18 [118,
119]a n dI L - 1 α [120]. Inﬁltrating macrophages in the
kidney have been described in various kidney diseases
including glomerulonephritis, diabetic nephropathy, renal
ablation and unilateral ureteric obstruction. In various mod-
els of glomerulonephritis, production of proinﬂammatory
cytokinesandchemokines,forexample,iNOS,TNF-α,IL -1β
MCP-1, MIF, and NK-kB by macrophages is thought to play
a role in the pathogenesis of the disease [121]. Macrophage-
mediatedinﬂammationintheinterstitiumoftheouterstripe
oftheoutermedullahasbeendescribedearlyinthecourseof
ischemic AKI in the rat [122, 123]a n dm o u s e[ 67, 68, 124].
Depletion of macrophages in the kidney during AKI using
liposomal encapsulated clodronate [60, 67, 68]o rg e n e t i c
techniques [124] results in protection against ischemic AKI.
An anti-B7-1 antibody blocked mononuclear cell adherence
in vasa recta in rats and attenuated ischemic AKI both
functionally and histologically [123]. Reduced postischemic
macrophage inﬁltration and interstitial ﬁbrosis are seen in
osteopontin knockout mice [125].
The mechanism of protection against ischemic AKI by
macrophage depletion is not known. To answer the question
whether IL-18 from macrophages is contributing to the
development of AKI, the eﬀect of adoptive transfer of
wild type and IL-18 deﬁcient macrophages in macrophage-
depleted mice with AKI was determined. The aim was to
demonstrate that adoptive transferof wild type macrophages
reversed the protection produced by macrophage depletion
and that adoptive transfer of macrophages deﬁcient in IL-
18 did not reverse the protection. Adoptive transfer of
the peritoneal macrophages deﬁcient in IL-18 reversed the
protection against ischemic AKI to the same degree as
wild type macrophages suggesting that ischemic AKI is
independent of IL-18 production by macrophages [40].
Cisplatin-induced AKI is associated with increased renal
myeloperoxidase, which is produced by neutrophils and
macrophages [45, 108]. In vitro studies show that cisplatin
administration increases macrophage-mediated cytotoxicity
against neoplastic cells [126]. In addition, macrophage renal
inﬁltration was recently shown to occur late in the course of
cisplatin-induced AKI [127]. However, macrophage deple-
tion using liposomal encappsulated clodronate was not
protective in a mouse model of cisplatin-induced AKI [61].
8.5. Dendritic Cells. The principal DC function is the
induction of adaptive immune responses, in particular those
executed by T cells. Precursors of DCs are derived from the
bone marrow and enter the kidney from the bloodstream.
In the absence of “danger” signals like tissue damage or
local inﬂammation, DCs will remain immature and fail to
upregulate costimulatory molecules. Local inﬂammation or
tissue damage can induce DC maturation, which results in
the loss of phagocytic activity, expression of costimulatory
molecules, and interaction with T cells. It is unknown
whether these characteristics apply to DCs in the kidney
[128].
DCsareabundantlypresentintheinterstitiuminnormal
mouse kidneys [129]. These DCs expressed the DC marker
CD11c. Renal DCs resemble splenic DCs, but not peritoneal
macrophages, in morphology, lysosomal content, phagocytic
activity, microbicidal eﬀector functions, expression of T cell
costimulatory molecules, and ability to activate T cells. Renal
DCs also express MHC class II and costimulatory molecules
[129].DCsformacontiguousnetworkthroughouttheentire
kidney [130].
Renal DCs have been reported to play an important
role in ischemic AKI. Following kidney ischemia-perfusion,
resident dentritic cells release TNF, IL-6, MCP-1, and
RANTES and the depletion of DCs before ischemic injury
signiﬁcantly reduces TNF levels in the kidney [131].
There are interactions between NK cells and DCs that
are important in the inﬂammatory response. Activated NK
cells induce DC maturation. Immature DCs are vulnerable
to autologous NK-cell-mediated cytolysis while mature DCs
are protected. NK-cell-mediated DC activation is dependent
on tumor necrosis factor-alpha (TNF-alpha) and interferon-
gamma (IFN-gamma). In vitro, IL-12, IL-18, IL-15, and
IFN-alpha/beta production by activated DCs augments NK-
cell IFN-gamma production, proliferation, and cytotoxicity.
[132].
9.Endoplasmic ReticulumStressintheKidney
The ER functions in the regulation of protein biosynthesis,
protein folding, and the transport of synthesized proteins.
The ER detects the presence of unfolded or misfolded
proteins and protein chaperones catalyze protein folding
[133]. The accumulation of unfolded and misfolded proteins
in the ER lumen induces ER stress. ER stress results
in an adaptive response known as the unfolded protein
response (UPR) [134]. The UPR facilitates the adaptation
to stress and attempts to reestablish normal ER function
by activating calcium-dependent molecular chaperones like
glucose-regulated protein-78 (GRP78) (also known as BiP)
[134]. The production of reactive oxygen species (ROS)
during oxidative stress results in protein misfolding in
the ER Pharmacological activation of the UPR results in
functional and histological protection against AKI in a
mouse model [135, 136]. Bax inhibitor-1 (BI-1) is an ER
protein that suppresses cell death. BI-1 knockout mice
have worse ischemic liver and kidney injury compared
to wild-type mice suggesting that the cytoprotective gene8 Mediators of Inﬂammation
BI-1 provides intrinsic protection from ER stress [137].
The oxygen-regulated protein (ORP150) is an inducible ER
chaperone. Renal tubular epithelial cells transfected with
ORP150 were protected against hypoxic injury whereas
inhibitionofORP150madecellsmoresusceptibletohypoxic
injury [138]. Transcriptional regulators of genes involved in
the inﬂammatory response, for example, nuclear factor-kB
( N F - k B )a r ea c t i v a t e db yE Rs t r e s s[ 134]. In summary, ER
stress in the kidney is a novel mediator of kidney injury.
10. Summary
In summary, in AKI, both renal endothelial cells and
proximal tubular epithelial cells produce cytokines and
chemokines that result in inﬁltration of inﬂammatory
cells (neutrophils, lymphocytes, macrophages, NK cells,
Treg cells) into the interstitium of the kidney (Figure 1).
Inﬂammatory cells in the kidney produce pro- and anti-
inﬂammatorycytokinesthatmayfurtherincreaseordecrease
inﬂammation in the kidney. The mechanism by which
adherent and inﬁltrating leukocytes cause ischemic tubular
epithelialandendothelialinjuryisunclear,butlikelyinvolves
the release of oxygen radicals [139, 140], the release of potent
vasoconstrictors including the prostaglandins, leukotrienes,
and thromboxanes [141], as well as direct endothelial injury
via release of endothelin and a decrease in NO [142, 143].
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